Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Methods to Monitor Molecular Consistency of Oral Polio Vaccine.

Chumakov KM.

Methods Mol Biol. 2016;1387:263-77. doi: 10.1007/978-1-4939-3292-4_14.

PMID:
26983740
2.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28. Review.

PMID:
23550968
3.

Expert review on poliovirus immunity and transmission.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Review.

PMID:
22804479
4.

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM.

Antivir Ther. 2011;16(7):999-1004. doi: 10.3851/IMP1838.

PMID:
22024515
5.

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM.

Clin Vaccine Immunol. 2011 Aug;18(8):1387-90. doi: 10.1128/CVI.05147-11. Epub 2011 Jun 29.

6.

Universal oligonucleotide microarray for sub-typing of Influenza A virus.

Ryabinin VA, Kostina EV, Maksakova GA, Neverov AA, Chumakov KM, Sinyakov AN.

PLoS One. 2011 Apr 29;6(4):e17529. doi: 10.1371/journal.pone.0017529.

7.

Cleavage of eukaryotic initiation factor eIF5B by enterovirus 3C proteases.

de Breyne S, Bonderoff JM, Chumakov KM, Lloyd RE, Hellen CU.

Virology. 2008 Aug 15;378(1):118-22. doi: 10.1016/j.virol.2008.05.019. Epub 2008 Jun 24.

8.

Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.

Neznanov N, Dragunsky EM, Chumakov KM, Neznanova L, Wek RC, Gudkov AV, Banerjee AK.

PLoS One. 2008 Apr 2;3(4):e1887. doi: 10.1371/journal.pone.0001887.

9.

Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin.

Neznanov N, Kondratova A, Chumakov KM, Neznanova L, Kondratov R, Banerjee AK, Gudkov AV.

DNA Cell Biol. 2008 Apr;27(4):191-8.

PMID:
18067462
10.

[An oligonucleotide microarray for detection and discrimination of orthopoxviruses based on oligonucleotide sequences of two viral genes].

Riabinin VA, Shundrin LA, Kostina EV, Laassri M, Chizhikov VE, Maksakova GA, Baturina OA, Pozdniakova LD, Feshchenko MV, Shchelkunov SN, Chumakov KM, Siniakov AN.

Mol Gen Mikrobiol Virusol. 2006;(4):23-30. Russian.

PMID:
17094655
11.

Genotyping of measles virus in clinical specimens on the basis of oligonucleotide microarray hybridization patterns.

Neverov AA, Riddell MA, Moss WJ, Volokhov DV, Rota PA, Lowe LE, Chibo D, Smit SB, Griffin DE, Chumakov KM, Chizhikov VE.

J Clin Microbiol. 2006 Oct;44(10):3752-9.

12.

Poliovirus-binding inhibition ELISA for evaluation of immune response to oral poliovirus vaccine: a possible alternative to the neutralization test.

Ivanov AP, Dragunsky EM, Ivanova OE, Rezapkin GV, Potapova SG, Chumakov KM.

Hum Vaccin. 2005 May-Jun;1(3):102-5. Epub 2005 May 5.

PMID:
17012865
13.

Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.

Dragunsky EM, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.

J Infect Dis. 2006 Sep 15;194(6):804-7. Epub 2006 Aug 16.

PMID:
16941347
14.

Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.

Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, Baykova OY, Chumakov KM, Agol VI.

J Virol. 2006 Mar;80(6):2641-53.

15.

1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.

Ivanov AP, Dragunsky EM, Chumakov KM.

J Infect Dis. 2006 Feb 15;193(4):598-600. Epub 2006 Jan 12.

PMID:
16425140
16.

Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection.

Neznanov N, Chumakov KM, Neznanova L, Almasan A, Banerjee AK, Gudkov AV.

J Biol Chem. 2005 Jun 24;280(25):24153-8. Epub 2005 Apr 21.

17.

Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, Krasnoproshina LI, Romanenkova NI, Rozaeva NR, Sirota L, Agol VI, Chumakov KM.

J Virol. 2005 Jan;79(2):1062-70.

18.

Mapping of genomic segments of influenza B virus strains by an oligonucleotide microarray method.

Ivshina AV, Vodeiko GM, Kuznetsov VA, Volokhov D, Taffs R, Chizhikov VI, Levandowski RA, Chumakov KM.

J Clin Microbiol. 2004 Dec;42(12):5793-801.

19.

Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.

Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.

J Infect Dis. 2004 Oct 15;190(8):1404-12. Epub 2004 Sep 20.

PMID:
15378432
20.

Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI.

J Virol. 2003 Dec;77(23):12460-5.

21.

Stability of the prion protein-encoding (PRNP) gene in HeLa cells.

Amexis G, Ridge J, Cervenakova L, Enterline JC, Chumakov KM, Asher DM.

Biologicals. 2003 Mar;31(1):83-6.

PMID:
12623063
22.

Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI.

J Virol. 2002 Jul;76(13):6791-9.

23.

Poliovirus protein 3A inhibits tumor necrosis factor (TNF)-induced apoptosis by eliminating the TNF receptor from the cell surface.

Neznanov N, Kondratova A, Chumakov KM, Angres B, Zhumabayeva B, Agol VI, Gudkov AV.

J Virol. 2001 Nov;75(21):10409-20.

24.

Increased safety level of serotype 3 Sabin oral poliomyelitis vaccine lots by improved seed virus, and tissue culture and virus infection conditions.

Dörsam V, Weimer T, Schmeel A, Hein B, Enssle K, Chumakov KM, Fibi MR.

Vaccine. 2000 May 8;18(22):2435-43.

PMID:
10738101
25.

Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines.

Chumakov KM.

Dev Biol Stand. 1999;100:67-74. No abstract available.

PMID:
10616177
26.

Reevaluation of nucleotide sequences of wild-type and attenuated polioviruses of type 3.

Rezapkin GV, Douthitt M, Dragunsky E, Chumakov KM.

Virus Res. 1999 Dec 15;65(2):111-9.

PMID:
10581384
27.

Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.

Rezapkin GV, Fan L, Asher DM, Fibi MR, Dragunsky EM, Chumakov KM.

Virology. 1999 May 25;258(1):152-60.

28.

Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.

Rezapkin GV, Alexander W, Dragunsky E, Parker M, Pomeroy K, Asher DM, Chumakov KM.

Virology. 1998 Jun 5;245(2):183-7.

30.
31.

Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys.

Lu Z, Rezapkin GV, Douthitt MP, Ran Y, Asher DM, Levenbook IS, Chumakov KM.

J Gen Virol. 1996 Feb;77 ( Pt 2 ):273-80.

PMID:
8627231
32.

Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.

Rezapkin GV, Norwood LP, Taffs RE, Dragunsky EM, Levenbook IS, Chumakov KM.

Virology. 1995 Aug 20;211(2):377-84.

33.
34.

Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.

Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS.

Virology. 1995 Jun 1;209(2):366-73.

35.

Reverse transcriptase can inhibit PCR and stimulate primer-dimer formation.

Chumakov KM.

PCR Methods Appl. 1994 Aug;4(1):62-4. No abstract available.

36.

Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.

Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS.

Virology. 1994 Jul;202(1):370-8.

PMID:
8009849
37.

Use of anti-TNF-alpha antiserum to investigate toxic alveolitis arising from cotton dust exposure.

Shvedova AA, Kramarik JA, Keohavong P, Chumakov KM, Karol MH.

Exp Lung Res. 1994 Jul-Aug;20(4):297-315.

PMID:
7988494
38.

Consistent selection of mutations in the 5'-untranslated region of oral poliovirus vaccine upon passaging in vitro.

Chumakov KM, Dragunsky EM, Norwood LP, Douthitt MP, Ran Y, Taffs RE, Ridge J, Levenbook IS.

J Med Virol. 1994 Jan;42(1):79-85.

PMID:
8308524
39.

Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC).

Lu Z, Douthitt MP, Taffs RE, Ran Y, Norwood LP, Chumakov KM.

PCR Methods Appl. 1993 Dec;3(3):176-80.

40.

The enhanced mutagenic potential of the MucAB proteins correlates with the highly efficient processing of the MucA protein.

Hauser J, Levine AS, Ennis DG, Chumakov KM, Woodgate R.

J Bacteriol. 1992 Nov;174(21):6844-51.

41.

Bacillus methanolicus sp. nov., a new species of thermotolerant, methanol-utilizing, endospore-forming bacteria.

Arfman N, Dijkhuizen L, Kirchhof G, Ludwig W, Schleifer KH, Bulygina ES, Chumakov KM, Govorukhina NI, Trotsenko YA, White D, et al.

Int J Syst Bacteriol. 1992 Jul;42(3):439-45.

PMID:
1380290
42.

RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence.

Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS.

J Virol. 1992 Feb;66(2):966-70.

43.

Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS.

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):199-203.

44.

Taxonomic studies on methylotrophic bacteria by 5S ribosomal RNA sequencing.

Bulygina ES, Galchenko VF, Govorukhina NI, Netrusov AI, Nikitin DI, Trotsenko YA, Chumakov KM.

J Gen Microbiol. 1990 Mar;136(3):441-6.

PMID:
2391487
45.

Sulfobacillus thermosulfidooxidans: a new lineage of bacterial evolution?

Karavajko GI, Bulygina ES, Tsaplina IA, Bogdanova TI, Chumakov KM.

FEBS Lett. 1990 Feb 12;261(1):8-10.

47.

[Detection of a sodium pump in the terminal segment of the bacterial respiratory chain].

Verkhovskaia ML, Semeĭkina AL, Skulachev VP, Bulygina ES, Chumakov KM.

Biokhimiia. 1989 Sep;54(9):1457-66. Russian.

PMID:
2590685
48.

The Na+-motive terminal oxidase activity in an alkalo- and halo-tolerant Bacillus.

Semeykina AL, Skulachev VP, Verkhovskaya ML, Bulygina ES, Chumakov KM.

Eur J Biochem. 1989 Aug 15;183(3):671-8.

49.
50.

[Trees of maximum approximation: topologic approach to the task of constructing trees of maximum approximation].

Iushmanov SV, Chumakov KM.

Zh Evol Biokhim Fiziol. 1989 Jul-Aug;25(4):532-6. Russian. No abstract available.

PMID:
2596210

Supplemental Content

Loading ...
Support Center